Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial.
Saved in:
| Title: | Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial. |
|---|---|
| Authors: | Ding, Yiling1 (AUTHOR), Wang, Chunping2,3 (AUTHOR), Shu, Yamin1 (AUTHOR), Wang, Jinglin4 (AUTHOR) linlinvc202@163.com, Zhang, Qilin4 (AUTHOR) qilinzhang88@163.com |
| Source: | Journal of Pharmaceutical Policy & Practice. Dec2025, Vol. 18 Issue 1, p1-18. 18p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
